Peter Marks says Acting Commissioner Janet Woodcock’s tenure running the FDA has been no different than if a permanent commissioner were in place.
The US Food and Drug Administration has not been stuck in neutral while waiting for a new permanent commissioner, according to Center for Biologics Evaluation and Research Director Peter Marks.
In fact, Marks said that he cannot tell the difference between operations with a permanent commissioner and Acting Commissioner Janet...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
